CSPC Pharmaceutical Group Limited

SEHK:1093 Voorraadrapport

Marktkapitalisatie: HK$61.4b

CSPC Pharmaceutical Group Toekomstige groei

Future criteriumcontroles 0/6

CSPC Pharmaceutical Group is forecast to grow earnings and revenue by 1.2% and 3% per annum respectively. EPS is expected to grow by 1% per annum. Return on equity is forecast to be 13.5% in 3 years.

Belangrijke informatie

1.2%

Groei van de winst

1.0%

Groei van de winst per aandeel

Pharmaceuticals winstgroei11.1%
Inkomstengroei3.0%
Toekomstig rendement op eigen vermogen13.5%
Dekking van analisten

Good

Laatst bijgewerkt01 Nov 2024

Recente toekomstige groei-updates

Recent updates

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Oct 16
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%

Sep 30
Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%

CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

Aug 08
CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Jun 17
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

May 29
CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

May 21
CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

Apr 29
CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

Apr 22
There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

Apr 01
CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jan 22
CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

Jan 04
Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Oct 22
Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

Sep 21
Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Jul 09
CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

Jun 20
Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

Jun 01
CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

Apr 04
CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

Mar 12
CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease

Dec 26
We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease

Winst- en omzetgroeiprognoses

SEHK:1093 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202635,4956,4975,5027,82625
12/31/202533,6406,1894,9737,34628
12/31/202432,1265,9744,7527,24025
6/30/202431,6545,9272,6724,284N/A
3/31/202432,3806,057N/AN/AN/A
12/31/202331,4505,8732,2904,179N/A
9/30/202331,3066,118N/AN/AN/A
6/30/202331,4076,0921,9344,690N/A
3/31/202331,1166,116N/AN/AN/A
12/31/202230,9376,0914,9227,627N/A
9/30/202230,7215,738N/AN/AN/A
6/30/202229,6555,5094,0946,151N/A
3/31/202229,0075,538N/AN/AN/A
12/31/202127,8675,6052,8874,637N/A
9/30/202126,3695,977N/AN/AN/A
6/30/202126,1755,9085,8657,053N/A
3/31/202125,5515,472N/AN/AN/A
12/31/202024,9425,1605,3626,740N/A
9/30/202024,5584,421N/AN/AN/A
6/30/202023,5154,1503,1294,614N/A
3/31/202022,7353,922N/AN/AN/A
12/31/201922,1033,7141,8353,784N/A
9/30/201921,3353,625N/AN/AN/A
6/30/201920,1353,4541,3703,743N/A
3/31/201918,8353,294N/AN/AN/A
12/31/201817,7173,0811,9223,795N/A
9/30/201816,8772,905N/AN/AN/A
6/30/201815,7292,7341,8273,352N/A
3/31/201813,9592,443N/AN/AN/A
12/31/201712,8772,307N/A2,738N/A
9/30/201712,2032,195N/AN/AN/A
6/30/201711,6592,068N/A2,811N/A
3/31/201711,3831,979N/AN/AN/A
12/31/201611,0751,881N/A2,611N/A
9/30/201610,4391,711N/AN/AN/A
6/30/201610,1181,607N/A2,147N/A
3/31/20169,6561,473N/AN/AN/A
12/31/20159,5451,395N/A1,884N/A
9/30/20159,2841,305N/AN/AN/A
6/30/20159,0721,192N/A1,192N/A
3/31/20158,9191,126N/AN/AN/A
12/31/20148,7621,015N/A1,445N/A
9/30/20148,423896N/AN/AN/A
6/30/20148,197849N/A1,059N/A
3/31/20148,001814N/AN/AN/A
12/31/20137,768760N/A636N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 1093's forecast earnings growth (1.2% per year) is below the savings rate (2.3%).

Winst versus markt: 1093's earnings (1.2% per year) are forecast to grow slower than the Hong Kong market (11.5% per year).

Hoge groeiwinsten: 1093's earnings are forecast to grow, but not significantly.

Omzet versus markt: 1093's revenue (3% per year) is forecast to grow slower than the Hong Kong market (7.7% per year).

Hoge groei-inkomsten: 1093's revenue (3% per year) is forecast to grow slower than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: 1093's Return on Equity is forecast to be low in 3 years time (13.5%).


Ontdek groeibedrijven